Compare Stocks: GHRS, DFTX, INDV, and LQDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DFTX Definium Therapeutics	$38.10 +2.8%	$38.27	$10.46 ▼ $49.70	$5.12B	2.19	2.24 million shs	1.67 million shs
GHRS GH Research	$20.71 +3.4%	$24.56	$12.04 ▼ $31.44	$1.42B	1.32	302,440 shs	198,718 shs
INDV Indivior	$34.77 +0.1%	$35.41	$24.74 ▼ $42.81	$4.10B	0.87	2.21 million shs	1.53 million shs
LQDA Liquidia	$45.72 +0.6%	$54.69	$22.05 ▼ $93.61	$4.09B	0.61	2.28 million shs	2.24 million shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DFTX Definium Therapeutics	+3.92%	+5.67%	+2.52%	-12.05%	+189.01%
GHRS GH Research	+4.38%	+4.43%	-16.02%	-28.45%	+39.90%
INDV Indivior	+0.46%	-0.14%	-3.07%	-13.42%	+40.11%
LQDA Liquidia	+3.89%	+25.01%	-33.60%	-47.66%	+99.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DFTX Definium Therapeutics	$38.10 +2.8%	$38.27	$10.46 ▼ $49.70	$5.12B	2.19	2.24 million shs	1.67 million shs
GHRS GH Research	$20.71 +3.4%	$24.56	$12.04 ▼ $31.44	$1.42B	1.32	302,440 shs	198,718 shs
INDV Indivior	$34.77 +0.1%	$35.41	$24.74 ▼ $42.81	$4.10B	0.87	2.21 million shs	1.53 million shs
LQDA Liquidia	$45.72 +0.6%	$54.69	$22.05 ▼ $93.61	$4.09B	0.61	2.28 million shs	2.24 million shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DFTX Definium Therapeutics	+3.92%	+5.67%	+2.52%	-12.05%	+189.01%
GHRS GH Research	+4.38%	+4.43%	-16.02%	-28.45%	+39.90%
INDV Indivior	+0.46%	-0.14%	-3.07%	-13.42%	+40.11%
LQDA Liquidia	+3.89%	+25.01%	-33.60%	-47.66%	+99.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DFTX Definium Therapeutics	2.95	Moderate Buy	$66.00	73.23% Upside
GHRS GH Research	2.75	Moderate Buy	$45.00	117.29% Upside
INDV Indivior	3.00	Buy	$45.50	30.86% Upside
LQDA Liquidia	2.42	Hold	$72.85	59.33% Upside

Current Analyst Ratings Breakdown

Latest GHRS, DFTX, INDV, and LQDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	INDV Indivior	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$43.00 ➝ $45.00
10/19/2026	DFTX Definium Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/15/2026	DFTX Definium Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	GHRS GH Research	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	LQDA Liquidia	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$65.00
10/15/2026	LQDA Liquidia	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$58.00 ➝ $65.00
10/14/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$30.00 ➝ $33.00
10/14/2026	LQDA Liquidia	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Outperform	$59.00
10/14/2026	LQDA Liquidia	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$70.00
10/14/2026	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$72.00 ➝ $58.00
10/9/2026	DFTX Definium Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$84.00

(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	$3.36 per share	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	$4.51 per share	N/A
INDV Indivior	$1.33B	3.08	$2.74 per share	12.68	($0.78) per share	-44.58
LQDA Liquidia	$158.32M	25.85	N/A	N/A	$0.51 per share	89.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DFTX Definium Therapeutics	-$183.79M	-$3.43	N/A	N/A	N/A	N/A	-84.01%	-63.66%	N/A
GHRS GH Research	-$48.26M	-$1.00	N/A	N/A	N/A	N/A	-20.86%	-20.12%	11/5/2026 (Estimated)
INDV Indivior	$210M	$2.79	12.46	9.08	N/A	26.65%	-283.11%	36.85%	10/29/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	33.37	21.46	0.37	30.74%	149.65%	36.30%	11/2/2026 (Estimated)

Latest GHRS, DFTX, INDV, and LQDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	GHRS GH Research	-$0.3122	N/A	N/A	N/A	N/A	N/A
11/2/2026	Q3 2026	LQDA Liquidia	$0.9220	N/A	N/A	N/A	$214.18 million	N/A
10/29/2026	Q3 2026	INDV Indivior	$1.06	N/A	N/A	N/A	$329.35 million	N/A
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	DFTX Definium Therapeutics	-$0.55	-$1.44	-$0.89	-$1.44	N/A	N/A
8/6/2026	Q2 2026	GHRS GH Research	-$0.2860	-$0.23	+$0.0560	-$0.23	N/A	N/A
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A

Latest GHRS, DFTX, INDV, and LQDA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/16/2026	INDV Indivior	special	$8.13			10/30/2026	11/6/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DFTX Definium Therapeutics	0.04	6.95	6.95
GHRS GH Research	N/A	28.70	28.70
INDV Indivior	N/A	0.84	0.66
LQDA Liquidia	0.63	2.31	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DFTX Definium Therapeutics	27.91%
GHRS GH Research	56.90%
INDV Indivior	60.33%
LQDA Liquidia	64.54%

Insider Ownership

Company	Insider Ownership
DFTX Definium Therapeutics	2.40%
GHRS GH Research	N/A
INDV Indivior	0.74%
LQDA Liquidia	25.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DFTX Definium Therapeutics	40	134.37 million	131.14 million	Optionable
GHRS GH Research	73	68.61 million	N/A	Optionable
INDV Indivior	838	118.03 million	117.16 million	Optionable
LQDA Liquidia	216	89.51 million	66.60 million	Optionable

GHRS, DFTX, INDV, and LQDA Headlines

Recent News About These Companies

Liquidia (NASDAQ:LQDA) Insider Sells 688 Shares of Company Stock

22 minutes ago | marketbeat.com

Liquidia (NASDAQ:LQDA) CAO Sells $68,283.39 in Stock

22 minutes ago | marketbeat.com

Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?

4 hours ago | zacks.com

Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?

October 26 at 11:01 AM | zacks.com

Liquidia (LQDA) Set to Release Earnings on Monday

October 26 at 4:55 AM | marketbeat.com

Can Liquidia (LQDA) Still Justify Its Price After Settlement?

October 24, 2026 | finance.yahoo.com

Liquidia (NASDAQ:LQDA) Stock Price Up 7.2% - Should You Buy?

October 23, 2026 | marketbeat.com

Liquidia consensus price target decreased by 26.00% to $58.01

October 23, 2026 | msn.com

Liquidia Corporation (NASDAQ:LQDA) Stock Has Consensus Price Target of $72.85 According to Analysts

October 23, 2026 | americanbankingnews.com

Liquidia Corporation (LQDA) - What Are Researchers Thinking About This Stock?

October 23, 2026 | marketbeat.com

Liquidia stock: BofA raises target for Liquidia stock to USD 42

October 22, 2026 | ad-hoc-news.deA

Liquidia Is A Bargain Today

October 22, 2026 | seekingalpha.com

Liquidia Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money on Your LQDA Investments

October 21, 2026 | newsfilecorp.comN

HC Wainwright lifts target for Liquidia stock from USD 58 to USD 65

October 20, 2026 | ad-hoc-news.deA

FY2028 EPS Estimates for Liquidia Increased by HC Wainwright

October 19, 2026 | americanbankingnews.com

Liquidia Stock Gets Stronger EPS Estimate from HC Wainwright

October 19, 2026 | marketbeat.com

HC Wainwright Forecasts Strong Price Appreciation for Liquidia (NASDAQ:LQDA) Stock

October 17, 2026 | americanbankingnews.com

Why Liquidia (LQDA) Is Up 24.1% After Striking Costly Peace Deal On YUTREPIA Litigation

October 15, 2026 | finance.yahoo.com

LifeSci Capital upgrades Liquidia to outperform from market perform

October 15, 2026 | msn.com

Liquidia (NASDAQ:LQDA) Price Target Raised to $65.00

October 15, 2026 | marketbeat.com

How Much Downside Is Left In Liquidia Stock?

October 15, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, DFTX, INDV, and LQDA Company Descriptions

Definium Therapeutics NASDAQ:DFTX

$38.10 +1.02 (+2.75%)

As of 04:00 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

GH Research NASDAQ:GHRS

$20.71 +0.69 (+3.45%)

Closing price 04:00 PM Eastern

Extended Trading

$20.74 +0.03 (+0.14%)

As of 04:14 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Indivior NASDAQ:INDV

$34.77 +0.05 (+0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$34.74 -0.03 (-0.08%)

As of 05:13 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Liquidia NASDAQ:LQDA

$45.72 +0.28 (+0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$45.50 -0.22 (-0.49%)

As of 05:28 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GHRS, DFTX, INDV, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GHRS, DFTX, INDV, and LQDA Earnings

Compare Dividends

Latest GHRS, DFTX, INDV, and LQDA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GHRS, DFTX, INDV, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, DFTX, INDV, and LQDA Company Descriptions

Definium Therapeutics NASDAQ:DFTX

GH Research NASDAQ:GHRS

Indivior NASDAQ:INDV

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GHRS, DFTX, INDV, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GHRS, DFTX, INDV, and LQDA Earnings

Compare Dividends

Latest GHRS, DFTX, INDV, and LQDA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GHRS, DFTX, INDV, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, DFTX, INDV, and LQDA Company Descriptions

Definium Therapeutics NASDAQ:DFTX

GH Research NASDAQ:GHRS

Indivior NASDAQ:INDV

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools